



(Advertisement)

Search

[Home](#) | [Specialties](#) | [Resource Centers](#) | [CME](#) | [PDA](#) | [Contributor Recruitment](#) | [!](#)


Janu

 Articles Images CME
 [Link](#)
You are in: [eMedicine Specialties](#) > [Pediatrics](#) > [Genetics And Metabolic Disease](#)

Aicardi Syndrome

Last Updated: April 19, 2005

Rate this Article

Email to a Colleague

Get CME/CE for article

Synonyms and related keywords: callosal agenesis, ocular abnormalities, syndrome of spasm-in-flexion, Aicardi's syndrome, brain malformations, agenesis of the corpus callosum, dysmorphic facies, cleft lip, cleft palate, seizure, infantile spasm, mental retardation, hemivertebrae, fused vertebrae, rib abnormalities, scoliosis, chorioretinal lacuna pathognomonic lesions, retinal colobomata

AUTHOR INFORMATION

Section 1 of 11

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Author: **Marc P Difazio, MD**, Chief, Child and Adolescent Neurology Clinic, Assistant Professor, Department of Neurology, Section of Child and Adolescent Neurology, Walter Reed Army Medical Center

Coauthor(s): **Ronald G Davis, MD**, Assistant Professor, Department of Neurology, Division of Child and Adolescent Neurology, Children's Hospital of Boston and Harvard University Medical School; **Marc P Difazio, MD**, is a member of the following medical societies: [Alpha Omega Alpha](#), [American Academy of Neurology](#), and [Child Neurology Society](#)

Editor(s): **James Bowman, MD**, Senior Scholar of Maclean Center for Clinical Medical Ethics, Professor Emeritus, Department of Pathology, University of Chicago; **Robert Konop, PharmD**, Director, Clinical Account Management, Ancillary Care Management; **Hagop Youssoufian, MD**, Medical Director, Adjunct Associate Professor, Clinical Discovery Department, Bristol-Myers Squibb; **Paul D Petry, DO, FACOP**, Assistant Professor, Department of Pediatrics, Division of Maternal Child Health, Northeast Regional Medical Center; and **Bruce A Buehler, MD**, Professor, Department of Pathology and Microbiology, Chairman, Department of Pediatrics, Director, Harlan Munroe Center for Human Genetics, University of Nebraska Medical Center

Disclosure

Pulmicort
RESPULES
(budesonide inhalation suspension)

0.25mg
2.5mg

Visit our website

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. PULMICORT RESPULES is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

(Advertisement)

INTRODUCTION

Section 2 of 11 [Back](#) [Top](#)[Author Information](#) [Introduction](#) [Clinical](#) [Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Background: In 1965, a French neurologist, Dr Jean Dennis Aicardi, described 8 children with infantile spasm-in-flexion, agenesis of the corpus callosum, and variable ocular abnormalities. This clinical scenario, already reported in 1949, was recognized as an entity distinct from congenital infections. An additional 7 patients were described in 1969, and, in 1972, Dennis and Bower established the Aicardi syndrome designation.

Further patient study demonstrated other less consistent characteristics outside the classic triad findings. These additional characteristics include abnormal facies, cleft lip and palate, and vertebral body abnormalities. Most children have a moderate-to-severe degree of mental retardation, although less severely affected children occasionally are described. To date, only 1 affected child has been reported as male.

Pathophysiology: At present, no etiology explains all the manifestations of Aicardi syndrome. Findings are ascribed to neural tube overdistension during embryogenesis at 4-8 weeks' gestation. Experimental evidence is lacking, and the cause remains unknown.

Frequency:

- **Internationally:** Although cases occur throughout the world, exact incidence and prevalence are unknown. In a series of children with infantile spasm, 2% had Aicardi syndrome. Given the phenotypic heterogeneity and diagnostic difficulties associated with young children, Aicardi syndrome may be a more frequent cause of mental retardation and seizure in girls than previously thought.

Mortality/Morbidity: Aicardi syndrome is often complicated by severe mental retardation, infantile epilepsy, and a resultant propensity to pulmonary complications. The condition often leads to death in the first decade. Sudden, unexplained death is common.

Race: The syndrome occurs in people of diverse racial backgrounds throughout the world with no noted racial predominance.

Sex: Aicardi syndrome is thought to be an X-linked dominant disorder lethal to males. Except for a single patient, all reported instances have been in females.

Age: Because Aicardi is a congenital syndrome, it is often first recognized during the neonatal period and infancy. Less severely affected individuals may live into childhood and adolescence, and diagnosis may be delayed. In one group of patients, diagnosis was delayed from 11-234 weeks from the onset of seizures.

CLINICAL

Section 3 of 11 [Back](#) [Top](#)[Author Information](#) [Introduction](#) [Clinical](#) [Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

History:

- Aicardi syndrome is often diagnosed in female infants only after the onset of seizures or the presence of dysmorphic facies prompts further evaluation.
- If only visual abnormalities or developmental delays are present, the condition may not be recognized until the onset of seizures or if ophthalmologic evaluations demonstrate characteristic chorioretinal lacunae.
- Seizures are a common initial manifestation, most frequently infantile spasm. Chevrie et al reported 97% of patients had infantile spasm, and the majority of these had seizures when younger than 3 months. Additional seizure types noted include hemiconvulsions, complex seizures, and focal motor seizures.
- Electroencephalogram (EEG) findings are not consistent. In the relevant clinical scenario, a suppression pattern arising independently from each hemisphere suggests Aicardi syndrome.
- Global developmental delay is uniform, and most patients have moderate-to-severe mental retardation. This characteristic is probably due to the combination of brain dysgenesis and intractable epilepsy, although some children may walk and, in rare cases, develop expressive language.
- Most of these children are unable to walk and are bedridden. Children with Aicardi syndrome typically lack even rudimentary abilities to interact with their environments.
- Ocular abnormalities limit visual ability, blinding most children. Certain malignancies occur frequently, including embryonic soft tissue carcinoma, hepatoblastoma, and angiosarcoma.

Physical:

- Ocular
 - Pathognomonic lesions, called chorioretinal lacunae, commonly cluster around the disc of the eye and are described as punched-out, white- or yellow-colored defects. Lesions characteristically lack pigment, a characteristic that helps to distinguish them from lesions seen in infectious chorioretinitis. Classic chorioretinal lacunae do not enlarge or progress. Although other ocular lesions exist in Aicardi syndrome, this manifestation is required for diagnosis.
 - Other common ocular lesions include the following:
 - Microphthalmos
 - Retrobulbar cyst
 - Cataract
 - Coloboma

- Retinal detachment
- Iris synechiae
- Craniofacial
 - Microcephaly, hemifacial asymmetry, microphthalmia, or plagiocephaly may be present.
 - Cleft lip and palate also occur with increased frequency.
- Musculoskeletal
 - Skeletal malformations are common but are not uniform in all patients.
 - Costovertebral abnormalities, such as hemivertebrae, fused vertebrae, and rib abnormalities, may be present.
 - Scoliosis resulting from these deformities can be disfiguring and disabling.
- Neurodevelopmental
 - Patients typically have profound mental retardation; however, the disease course can have a milder expression in some than was thought historically.
 - Some children may walk and speak, though rarely. One of the few studies to examine natural history indicates that 21% of patients could ambulate, and 29% could communicate. These abilities appeared independent of seizure frequency, EEG findings, or other features studied during the first year of life.
 - If present, hypotonia, spasticity, or hemiplegia may complicate gross motor development.

Causes:

- Causes of various clinical manifestations are unknown.
- Events early in gestation, probably in weeks 4-8, are suspected causes. The exact etiology of these events remains elusive, although considerations have included in utero exposure to mild hypoxia, and infections. Investigation of these potential etiologies has been unrevealing.
- A genetic basis for the syndrome is favored, specifically an X-linked dominant mutation with lethality in male hemizygotes. Spontaneous mutation is most likely because siblings appear spared, but parental gonadal mosaicism could be the basis for a reported pair of sisters with the condition.
- The only male patient has been described with an XXY genotype.
- Skewed X chromosome inactivation may account for some clinical heterogeneity. Skewing is increased in more severely affected patients.

DIFFERENTIALSSection 4 of 11 [Back](#) [Top](#)[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)[Chorioretinitis](#)**Other Problems to be Considered:**

Infantile spasm
Developmental delay
Mental retardation
Agenesis of the corpus callosum

WORKUP[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)**Lab Studies:**

- If the clinical scenario is convincing, extensive laboratory studies are not indicated.
 - Most children should have high-resolution karyotyping. If the diagnosis is doubtful, metabolic error and congenital infection.
 - If typical clinical findings manifest in a male, look for an XXY chromosomal pattern.
 - Children with partial manifestations may have translocations that can influence rep

Imaging Studies:

- Neuroimaging can delineate the degree of CNS dysgenesis and help evaluate other potential causes of epilepsy and developmental delay.
- MRI is preferred because its anatomic resolution is superior to CT scanning. Although the typical pattern of complete agenesis of the corpus callosum, partial agenesis and cortical dysplasia may not be evident.
- CT scanning can demonstrate calcifications (possible in congenital infections) better than MRI. If the diagnosis is questionable, CT scanning may be a helpful additional study.
- Plain radiographs can help confirm the diagnosis by showing skeletal malformations. The most common are costovertebral abnormalities, commonly affecting the thoracic vertebrae.

Other Tests:

- Ophthalmologic: Evaluation by an experienced ophthalmologist is crucial, especially if optic atrophy or retinal chamber abnormalities) makes the examination more difficult.

- Electroencephalographic
 - Abnormalities are common.
 - Most patients suffer from multiple types of seizures, but EEG findings are inconsistent.
 - A pattern highly suggestive of the diagnosis in the typical clinical context is the presence of a pattern arising independently from each hemisphere. In one case, the EEG prompt characteristics to establish the diagnosis.
 - EEG findings, along with diminished seizure frequency, commonly evolve as a patient's findings have shown an evolution from epileptic encephalopathy with suppression-like West syndrome and, subsequently, to the Lennox-Gastaut syndrome.

Histologic Findings: Multiple brain malformations are common and may include complete or partial agenesis of corpus callosum, cortical heterotopias, gyral malformation, and intraventricular cysts. These abnormalities are distributed uniformly, and the brain's appearance may be grossly normal, with a preserved corpus callosum. The parenchyma commonly reveals disordered cellular organization and disruption of the normal cortical architecture.

Chorioretinal lacunae are described as well-circumscribed, punched-out lesions in the retina and choroid. The region of these abnormalities contains severely disrupted retinal architecture; all retinal vessels, vessel number and caliber are decreased, and pigmentary ectopia and pigmentary epithelial holes are present.

TREATMENT

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Medical Care:

- Seizures
 - Use conventional epilepsy therapies for the many possible seizure manifestations.
 - Infantile spasm requires specific interventions and typically is unresponsive to conventional therapy. A seizure type may be especially recalcitrant to therapy.
 - Adrenocorticotrophic hormone (ACTH) is effective for some patients and should be used.
 - Vigabatrin, a more recently introduced therapy for infantile spasm, blocks gamma-aminobutyric acid (GABA)-T, an enzyme that breaks down GABA, the major inhibitory neurotransmitter. Concerns have been raised about possible ophthalmologic sequelae (eg, cone rod dystrophy) after using vigabatrin, it has been effective for infantile spasm without the serious side effects of ACTH. If retinal disruption from the congenital insult is deemed sufficient, the nature and sequelae of infantile spasm may outweigh the risks of using vigabatrin. Vigabatrin medication is not currently approved for use in the United States, which precludes its use.
- Pulmonary

- Profound mental retardation, immobilization, seizures, and scoliosis may contribute dysfunction.
- Patients have a shortened life span and commonly die from pulmonary infections.
- Aggressive pulmonary toilet and alternate feeding routes (eg, feeding tubes) may h deterioration.

Consultations:

- Consultation with a child neurologist is probably needed during the first year of life.
- A pediatric ophthalmologist is best able to confirm retinal lacunae.
- If the diagnosis is doubtful, or if subsequent children are planned, a geneticist with exper helpful.
- Consult a cardiac, pulmonary, or gastroenterologic specialist if complications arise from ; or feeding or aspiration difficulties.

Diet:

- No specific dietary recommendations exist.
- Use of the ketogenic diet to control seizures associated with this condition is not docume



Targeting Abdominal Obesity to Reduce Cardiovascular Risk in Patients With Type 2

This activity is composed of the following audio/slide presentations:

- Welcome and Program Introduction (Alan D. Cherrington, PhD)
- Why Abdominal Obesity Increases Metabolic and Cardiovascular Risk in Type 2 Diabetes: The Preclinical Evidence (Richard N. Bergman, PhD)
- The Endocannabinoid System: The Mechanisms Behind Metabolic Homeostasis and Imbalance (Stephen C. Woods, PhD)
- Endocannabinoid Blockade for Improving Glycemic Control and Lipids in Patients With Type 2 Diabetes (Priscilla Hollander, MD, PhD)
- Panel Discussion (Moderator Louis J. Aronne, MD, FACP, with panelists Richard Bergman, PhD; Alan D. Cherrington, PhD; Robert R. Henry, MD; Priscilla Hollander, MD, PhD; and Stephen C. Woods, PhD)

TAKE THIS FREE COURSE NOW >

MEDICATION

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Multiple medications are now available to treat infantile spasm, the most common initial epilep syndrome. Consider vigabatrin, although not FDA-approved, because of this disorder's ocular successful use in other conditions that have infantile spasm as a major manifestation. Vigabat the United States and cannot be considered the drug of choice. Initiate a detailed discussion w about the multiple medications available and the potential complications of each. Individualize patient and the capabilities and wishes of the family.

Drug Category: *Anticonvulsant agents* -- Effective management requires a detailed and a seizure types.

| | |
|--------------------------|--|
| Drug Name | Corticotropin (ACTH, Acthar) -- Precise mechanism for infantile spasms unknown. Theorized that ACTH suppresses corticotropin-releasing hormone (CRH), which is an excitatory neuropeptide. Infants with infantile spasms may have increased CRH. |
| Adult Dose | 40-80 U IM/SC qd/qod |
| Pediatric Dose | 20-40 U/d IM or 80 U IM qod for 3 mo or 1 mo after seizures cease |
| Contraindications | Documented hypersensitivity; osteoporosis; ocular herpes simplex; recent surgery; systemic fungal infections; scleroderma; CHF |
| | |

| | |
|--------------------------|--|
| Interactions | May decrease effects of aspirin, indomethacin, and insulin; diuretics increase effects |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Use lowest possible dose and reduce gradually if a decrease in dose desired; adrenocortical insufficiency may persist for months after discontinuing therapy (reinitiate corticosteroid therapy in any situation of stress); do not administer live attenuated viral or bacterial vaccines to individuals receiving immunosuppressive doses of corticotropin |
| Drug Name | Vigabatrin (Sabril) -- Currently not approved by FDA, and benefits of successful treatment of infantile spasm must be weighed against potentially serious ophthalmologic complications. May be obtained as an orphan drug from Aventis Pharmaceuticals for infantile spasm. Synthetic derivative of GABA. |
| Adult Dose | 2-3 g/d PO qd or divided bid; initiate at low doses and gradually titrate upward |
| Pediatric Dose | 50-150 mg/kg/d PO has been used for infantile spasm |
| Contraindications | Documented hypersensitivity |
| Interactions | Lowers phenytoin levels by 15-30%; may increase carbamazepine levels |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Closely monitor visual fields in patients able to comply with testing; discontinue drug (withdraw must be gradual) if visual symptoms occur (ie, concentric and predominantly nasal visual field constriction with temporal sparing); drowsiness is the most common adverse effect; psychotic effects (eg, hallucination, paranoia) or increased seizure activity may occur with abrupt initiation or withdrawal |

FOLLOW-UP

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Complications:

- Early sudden death is typical and is usually caused by pulmonary complications such as
- Seizures or their treatments (eg, ACTH) may also be associated with increased morbidity (infections) and death.
- The aforementioned malignancies may occur, and choroid plexus papillomas may cause

Prognosis:

- Prognosis is uniformly poor, with most children unable to walk or communicate; those who survive and require continuous care for their needs.

- Children commonly die in the first decade of life, although some have lived into the second decade.

Patient Education:

- For excellent patient education resources, visit eMedicine's [Brain and Nervous System C Children's Health Center](#). Also, see eMedicine's patient education articles [Epilepsy](#) and [Seizures](#).

MISCELLANEOUS

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)


Medical/Legal Pitfalls:

- To date, no evidence exists of an exogenous prenatal event that would explain this condition.
- Because of reports of affected siblings, discuss recurrence risk with the family.


PICTURES

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Caption: Picture 1. Cross-section of an eye in a patient with Aicardi syndrome. The arrow indicates chorioretinal lacunae.



 [View Full Size Image](#)

 [eMedicine Zoom View \(Interactive!\)](#)

Picture Type: Photo

BIBLIOGRAPHY

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

- Abe K, Mitsudome A, Ogata H, et al: [A case of Aicardi syndrome with moderate psychomotor retardation]. *Hattatsu* 1990 Jul; 22(4): 376-80[[Medline](#)].
- Aicardi J, Lefebvre J, Leriche-Koechlin A: A new syndrome: spasm in flexion, callosal agenesis, and mental retardation. *Electroenceph Clin Neurophysiol* 1965; 19: 609-10.
- Carney SH, Brodsky MC, Good WV, et al: Aicardi syndrome: more than meets the eye. *Neurology* 1991 Jun; 37(6): 419-24[[Medline](#)].
- Chevrie J, Aicardi J: The Aicardi syndrome. In: Pedley T, Meldrum B, eds. *Recent Advances in Epileptology*. Churchill Livingstone; 1986 3: 189-210.
- Darwish H: Aicardi syndrome. In: Gilman S, Goldstein G, eds. *Neurobase*. San Diego, CA: Elsevier; 1999: 2.
- Del Pero RA, Mets MB, Tripathi RC, Torczynski E: Anomalies of retinal architecture in Aicardi syndrome. *Ophthalmology* 1986 Nov; 104(11): 1659-64[[Medline](#)].

- Dennis J, Bower BD: The Aicardi syndrome. Dev Med Child Neurol 1972 Jun; 14(3): 382
- Fariello RG, Chun RW, Doro JM, et al: EEG recognition of Aicardi's syndrome. Arch Neurol [Medline].
- Ferrer I, Cusi M, Liarte A, Campistol J: A Golgi study of the polymicrogyric cortex in Aica 8(5): 518-25[Medline].
- Font R, Marines H, Cartwright J, Bauserman S: Aicardi syndrome. A clinicopathologic ca microscopic observations. Ophthalmology 1991 Nov; 98(11): 1727-31[Medline].
- Gardner WJ: Aicardi's syndrome: a result of overdistention of the neural tube. The absen 1982; 9(6): 419-23[Medline].
- Gorrone-Echebarria M: Genetics of Aicardi syndrome. Surv Ophthalmol 1993 Nov-Dec; 3
- Hamano S, Yagishita S, Kawakami M, et al: Aicardi syndrome: postmortem findings. Pec (4): 259-61[Medline].
- Menezes A, Enzenauer R, Buncic J: Aicardi syndrome--the elusive mild case. Br J Ophtl [Medline].
- Menezes A, MacGregor D, Buncic J: Aicardi syndrome: natural history and possible prec Neurol 1994 Nov; 11(4): 313-8[Medline].
- Molina J, Mateos F, Merino M, et al: Aicardi syndrome in two sisters. J Pediatr 1989 Aug
- Neidich J, Nussbaum R, Packer R, et al: Heterogeneity of clinical severity and molecular Pediatr 1990 Jun; 116(6): 911-7[Medline].
- Ohtsuka Y, Oka E, Terasaki T, Ohtahara S: Aicardi syndrome: a longitudinal clinical and study. Epilepsia 1993 Jul-Aug; 34(4): 627-34[Medline].
- Rosser T, Acosta M, Packer R: Aicardi syndrome: spectrum of disease and long-term pr Neurol 2002 Nov; 27(5): 343-6[Medline].
- Sabin A, Feldman H: Chorioretinopathy associated with other evidence of cerebral dama 1949; 35: 296-309.

NOTE:

Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, because medicine is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should consult other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. [FULL DISCLAIMER](#)

[Aicardi Syndrome excerpt](#)

© Copyright 2005, eMedicine.com, Inc.

[About Us](#) | [Privacy](#) | [Terms of Use](#) | [Contact Us](#) | [Advertise](#) | [Institutional Subscribers](#)



We subscribe to the [HONcode principles](#) of the [Health On the Net Foundation](#)

©1996-2005 eMed
[All Rights Reserved](#)